article thumbnail

Late-stage drug failures drive toxicology testing market growth

Drug Discovery World

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Marketing 147
article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Marketing 245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Drug discovery informatics market predicted to grow 12.6% by 2028

Drug Discovery World

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 130
article thumbnail

GLP-1 receptor agonists market to reach $125 billion by 2033

Drug Discovery World

Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. But there is an opportunity for new players to join the race, as the market is vast.

Marketing 130
article thumbnail

Where is the opportunity in the therapeutic antibody market?

Drug Discovery World

What you will learn: Where is the opportunity in the mAb market and where is the market heading? What effect has antibody engineering had on drug discovery and development? What are the main drivers and challenges for the market in the next ten years? The post Where is the opportunity in the therapeutic antibody market?

Marketing 130
article thumbnail

Where is the opportunity in the therapeutic antibody market?

Drug Discovery World

What you will learn: Where is the opportunity in the mAb market and where is the market heading? What effect has antibody engineering had on drug discovery and development? What are the main drivers and challenges for the market in the next ten years? The post Where is the opportunity in the therapeutic antibody market?

Marketing 147
article thumbnail

EC grants marketing authorisation for chronic hypoparathyroidism drug 

Drug Discovery World

The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily.

Marketing 130